Adaptive neoadjuvant endocrine therapy screens out prime population of ribociclib intensive adjuvant therapy
{{output}}
The latest data from the NATALEE trial showed the absolute 3-year invasive disease-free survival benefit was 4.9% between the experimental and control groups. That is to say, in the intermediate-risk hormone receptor positive/human epidermal growth factor rece... ...
